[go: up one dir, main page]

RU2018107409A3 - - Google Patents

Download PDF

Info

Publication number
RU2018107409A3
RU2018107409A3 RU2018107409A RU2018107409A RU2018107409A3 RU 2018107409 A3 RU2018107409 A3 RU 2018107409A3 RU 2018107409 A RU2018107409 A RU 2018107409A RU 2018107409 A RU2018107409 A RU 2018107409A RU 2018107409 A3 RU2018107409 A3 RU 2018107409A3
Authority
RU
Russia
Application number
RU2018107409A
Other versions
RU2773819C2 (ru
RU2018107409A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018107409A publication Critical patent/RU2018107409A/ru
Publication of RU2018107409A3 publication Critical patent/RU2018107409A3/ru
Application granted granted Critical
Publication of RU2773819C2 publication Critical patent/RU2773819C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018107409A 2015-08-05 2016-08-05 Белок, связанный с гликопротеином человека, композиция, фармацевтическая композиция, вектор экспрессии RU2773819C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179908.7 2015-08-05
EP15179908 2015-08-05
PCT/EP2016/068778 WO2017021539A2 (en) 2015-08-05 2016-08-05 Novel anti-human gpvi antibodies and uses thereof

Publications (3)

Publication Number Publication Date
RU2018107409A RU2018107409A (ru) 2019-09-05
RU2018107409A3 true RU2018107409A3 (ru) 2020-01-30
RU2773819C2 RU2773819C2 (ru) 2022-06-10

Family

ID=

Also Published As

Publication number Publication date
JP2018526990A (ja) 2018-09-20
BR112018002382A2 (pt) 2019-04-16
WO2017021539A3 (en) 2017-03-16
CN108289939B (zh) 2022-08-12
HK1256816A1 (en) 2019-10-04
IL257323B2 (en) 2024-01-01
MX2018001465A (es) 2019-01-31
KR102751174B1 (ko) 2025-01-07
PL3331553T3 (pl) 2022-09-12
CN108289939A (zh) 2018-07-17
SMT202200317T1 (it) 2022-09-14
IL257323A (en) 2018-03-29
LT3331553T (lt) 2022-09-12
EP3331553A2 (en) 2018-06-13
WO2017021539A2 (en) 2017-02-09
JP7277689B2 (ja) 2023-05-19
EP3331553B1 (en) 2022-06-29
ES2923677T3 (es) 2022-09-29
US20200384106A1 (en) 2020-12-10
CY1125400T1 (el) 2025-05-09
EP4091628A1 (en) 2022-11-23
DK3331553T3 (da) 2022-08-01
RU2018107409A (ru) 2019-09-05
SI3331553T1 (sl) 2022-11-30
RS63482B1 (sr) 2022-09-30
CA2994629A1 (en) 2017-02-09
HRP20220910T1 (hr) 2022-10-28
US20180236071A1 (en) 2018-08-23
BR112018002382A8 (pt) 2022-12-06
PT3331553T (pt) 2022-07-27
CN115925935A (zh) 2023-04-07
HUE059655T2 (hu) 2022-12-28
US10842870B2 (en) 2020-11-24
NZ739560A (en) 2024-01-26
JP2022025033A (ja) 2022-02-09
AU2016301969A1 (en) 2018-02-22
ZA201800804B (en) 2023-12-20
JP7076082B2 (ja) 2022-05-27
AU2016301969B2 (en) 2022-10-06
IL257323B1 (en) 2023-09-01
KR20180068952A (ko) 2018-06-22

Similar Documents

Publication Publication Date Title
BR112018004180A2 (ru)
BR112018002665A2 (ru)
BR112018002943A2 (ru)
BR112018002616A2 (ru)
BR112018002704A2 (ru)
BE2015C047I2 (ru)
BR0007468B1 (ru)
BR0302125B1 (ru)
CN303069466S (ru)
CN303068745S (ru)
BR0007487B1 (ru)
CN303068730S (ru)
BR0009182B1 (ru)
BR0006866B1 (ru)
BR0006854B1 (ru)
BR0006634B1 (ru)
CN303066943S (ru)
BR0005085B1 (ru)
CN303066603S (ru)
BR0007688B1 (ru)
BR0005041B1 (ru)
BR0007747B1 (ru)
CN303070772S (ru)
CN303071212S (ru)
BR0004687B1 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201210

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20210120

HZ9A Changing address for correspondence with an applicant